COMparison Between All immunoTherapies for Multiple Sclerosis (COMBAT-MS)
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
Compared with
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
- Dimethyl fumarate
Kelch-like ECH-associated protein 1 inhibitor
- Fingolimod
- Glatiramer acetate
Unknown
- Interferon beta-1b
Interferon alpha/beta receptor agonist
- Interferon beta-1a
Interferon alpha/beta receptor agonist
- Alemtuzumab
CAMPATH-1 antigen inhibitor
- Teriflunomide
Dihydroorotate dehydrogenase inhibitor
What it measured
Main measures
The primary endpoints in this study are:
Other measures (1)
Secondary analyses comprise comparisons between the different treatment regimens concerning:
Who could take part
Relapsing MS
Inclusion: The study population consists of all patients with CIS/RRMS diagnosed with the 2010 revised McDonald criteria who; Exclusion: Patients who at inclusion have the following characteristics are excluded from study participation;
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The two co-primary objectives of this study are
Papers
Loading reviews and guidelines…
Related trials
- Operetta III
Phase 2 · Not yet recruiting
Still running
- SOLI
Recruiting
Still running
- SONATA-MS
Recruiting
Still running
- HiHat
Phase 2 · Recruiting
Still running
- REDIFINE MS
Recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
History
Started
Mar 2017
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error